BRPI0921561A2 - derivado de 3-fenil-3-metóxi-pirrolidina, composição farmacêutica, uso do derivado de 3-fenil-3metóxi-pirrolidina, e , método para o tratamento, prevenção ou alívio de uma doença - Google Patents
derivado de 3-fenil-3-metóxi-pirrolidina, composição farmacêutica, uso do derivado de 3-fenil-3metóxi-pirrolidina, e , método para o tratamento, prevenção ou alívio de uma doençaInfo
- Publication number
- BRPI0921561A2 BRPI0921561A2 BRPI0921561A BRPI0921561A BRPI0921561A2 BR PI0921561 A2 BRPI0921561 A2 BR PI0921561A2 BR PI0921561 A BRPI0921561 A BR PI0921561A BR PI0921561 A BRPI0921561 A BR PI0921561A BR PI0921561 A2 BRPI0921561 A2 BR PI0921561A2
- Authority
- BR
- Brazil
- Prior art keywords
- methoxy
- phenyl
- pyrrolidine derivative
- alleviating
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200801657 | 2008-11-24 | ||
DKPA200801657 | 2008-11-24 | ||
PCT/EP2009/065676 WO2010058018A1 (en) | 2008-11-24 | 2009-11-24 | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0921561A2 true BRPI0921561A2 (pt) | 2018-10-09 |
BRPI0921561B1 BRPI0921561B1 (pt) | 2022-02-15 |
Family
ID=42197858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921561-1A BRPI0921561B1 (pt) | 2008-11-24 | 2009-11-24 | Derivado de 3-fenil-3-metóxi-pirrolidina, composição farmacêutica, uso do derivado de 3- fenil-3-metóxi-pirrolidina |
Country Status (19)
Country | Link |
---|---|
US (3) | US8673962B2 (pt) |
EP (2) | EP2367787B1 (pt) |
JP (1) | JP5716202B2 (pt) |
KR (1) | KR101660936B1 (pt) |
CN (1) | CN102224136B (pt) |
AU (1) | AU2009317156B2 (pt) |
BR (1) | BRPI0921561B1 (pt) |
CA (1) | CA2744308C (pt) |
DK (1) | DK2367787T3 (pt) |
ES (1) | ES2402713T3 (pt) |
HK (1) | HK1162173A1 (pt) |
IL (1) | IL212601A (pt) |
MX (1) | MX2011005036A (pt) |
NZ (1) | NZ592566A (pt) |
PL (1) | PL2367787T3 (pt) |
RU (1) | RU2524214C2 (pt) |
UA (1) | UA104152C2 (pt) |
WO (2) | WO2010058018A1 (pt) |
ZA (1) | ZA201103169B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009317155A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
DK2367787T3 (da) * | 2008-11-24 | 2013-03-25 | Nsab Af Neurosearch Sweden Ab | 3-phenyl-3-methoxypyrrolidinderivater som modulatorer af kortikal katekolaminerg neurotransmission |
CN102766079B (zh) * | 2011-05-06 | 2015-04-08 | 上海医药工业研究院 | 一类吡咯烷衍生物、其制备方法及应用 |
PT3297987T (pt) * | 2015-05-20 | 2019-06-19 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
PT3541784T (pt) | 2016-11-18 | 2023-11-22 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
EP3625213B1 (en) | 2017-05-19 | 2023-03-08 | Integrative Research Laboratories Sweden AB | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine fumarate, a process for its preparation and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1144279B (de) * | 1957-09-26 | 1963-02-28 | Robins Co Inc A H | Verfahren zur Herstellung von 3-Aryl-3-hydroxypyrrolidinen und deren Salzen |
US3119907A (en) | 1960-12-30 | 1964-01-28 | Texas Instruments Inc | Electromechanical commutator with rolling contact-type structure |
US3118907A (en) * | 1961-08-14 | 1964-01-21 | Mead Johnson & Co | 3-substituted-3-pyrrolidinols |
US3647790A (en) * | 1969-04-08 | 1972-03-07 | American Home Prod | Ouinoxalinyl-oxazolidines and -oxazines |
EP0641320B1 (en) | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
EP0586229A1 (en) * | 1992-09-01 | 1994-03-09 | Zeneca Limited | 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors |
AU4444393A (en) | 1992-09-01 | 1994-03-10 | Zeneca Limited | Pyrrolidine derivatives |
RU2470013C2 (ru) * | 2007-04-12 | 2012-12-20 | НСАБ, Филиаль ау НьюроСёрч Свиден АБ, Сверийе | N-оксидные и/или ди-n-оксидные производные стабилизаторов/модуляторов рецепторов дофамина, проявляющие улучшенные профили сердечно-сосудистых побочных эффектов |
DE602008006720D1 (de) | 2007-06-05 | 2011-06-16 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpyrrolidine als modulatoren der kortikalen katecholaminergen neurotransmission |
KR20100038295A (ko) | 2007-06-05 | 2010-04-14 | 엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게 | 피질 카테콜아민성 신경 전달의 조정자로서의 이치환된 페닐피롤리딘 |
US20110257148A1 (en) | 2008-11-24 | 2011-10-20 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 1-alkyl-3-hydroxy-3-phenylazetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
AU2009317155A1 (en) | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
DK2367787T3 (da) | 2008-11-24 | 2013-03-25 | Nsab Af Neurosearch Sweden Ab | 3-phenyl-3-methoxypyrrolidinderivater som modulatorer af kortikal katekolaminerg neurotransmission |
-
2009
- 2009-11-24 DK DK09759723.1T patent/DK2367787T3/da active
- 2009-11-24 US US13/130,438 patent/US8673962B2/en active Active
- 2009-11-24 NZ NZ592566A patent/NZ592566A/xx unknown
- 2009-11-24 CN CN200980146669.9A patent/CN102224136B/zh active Active
- 2009-11-24 EP EP09759723A patent/EP2367787B1/en active Active
- 2009-11-24 US US13/130,482 patent/US20110257242A1/en not_active Abandoned
- 2009-11-24 PL PL09759723T patent/PL2367787T3/pl unknown
- 2009-11-24 WO PCT/EP2009/065676 patent/WO2010058018A1/en active Application Filing
- 2009-11-24 ES ES09759723T patent/ES2402713T3/es active Active
- 2009-11-24 UA UAA201105529A patent/UA104152C2/ru unknown
- 2009-11-24 JP JP2011536893A patent/JP5716202B2/ja active Active
- 2009-11-24 WO PCT/EP2009/065678 patent/WO2010058019A1/en active Application Filing
- 2009-11-24 RU RU2011120817/04A patent/RU2524214C2/ru active
- 2009-11-24 AU AU2009317156A patent/AU2009317156B2/en active Active
- 2009-11-24 BR BRPI0921561-1A patent/BRPI0921561B1/pt active IP Right Grant
- 2009-11-24 CA CA2744308A patent/CA2744308C/en active Active
- 2009-11-24 KR KR1020117014551A patent/KR101660936B1/ko active IP Right Grant
- 2009-11-24 MX MX2011005036A patent/MX2011005036A/es active IP Right Grant
- 2009-11-24 EP EP09759724A patent/EP2367788A1/en not_active Withdrawn
-
2011
- 2011-04-29 ZA ZA2011/03169A patent/ZA201103169B/en unknown
- 2011-05-01 IL IL212601A patent/IL212601A/en active IP Right Grant
-
2012
- 2012-03-14 HK HK12102575.5A patent/HK1162173A1/xx unknown
-
2014
- 2014-01-22 US US14/160,901 patent/US9035073B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20110257241A1 (en) | 2011-10-20 |
KR20110087339A (ko) | 2011-08-02 |
MX2011005036A (es) | 2011-06-16 |
EP2367788A1 (en) | 2011-09-28 |
IL212601A0 (en) | 2011-07-31 |
RU2011120817A (ru) | 2012-12-27 |
KR101660936B1 (ko) | 2016-10-05 |
RU2524214C2 (ru) | 2014-07-27 |
JP2012509861A (ja) | 2012-04-26 |
US8673962B2 (en) | 2014-03-18 |
ZA201103169B (en) | 2012-09-26 |
CN102224136B (zh) | 2014-01-22 |
NZ592566A (en) | 2013-03-28 |
CA2744308A1 (en) | 2010-05-27 |
BRPI0921561B1 (pt) | 2022-02-15 |
AU2009317156A1 (en) | 2010-05-27 |
WO2010058019A1 (en) | 2010-05-27 |
ES2402713T3 (es) | 2013-05-08 |
HK1162173A1 (en) | 2012-08-24 |
EP2367787B1 (en) | 2013-01-09 |
PL2367787T3 (pl) | 2013-06-28 |
CA2744308C (en) | 2017-05-30 |
US20140135505A1 (en) | 2014-05-15 |
UA104152C2 (ru) | 2014-01-10 |
CN102224136A (zh) | 2011-10-19 |
US20110257242A1 (en) | 2011-10-20 |
IL212601A (en) | 2014-12-31 |
US9035073B2 (en) | 2015-05-19 |
DK2367787T3 (da) | 2013-03-25 |
AU2009317156B2 (en) | 2015-12-03 |
EP2367787A1 (en) | 2011-09-28 |
JP5716202B2 (ja) | 2015-05-13 |
WO2010058018A1 (en) | 2010-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI1008383A2 (pt) | composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
BRPI0913585A2 (pt) | composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios | |
BR112014011671A2 (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0917138A2 (pt) | composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação. | |
BRPI1005153A2 (pt) | composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
BRPI0815387A2 (pt) | composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição | |
BRPI0917013A2 (pt) | métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto | |
BRPI0912348A2 (pt) | composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças | |
BR112013026341A2 (pt) | composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
BRPI0815591A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio. | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BRPI0915084A2 (pt) | composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer | |
BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) |
|
B25G | Requested change of headquarter approved |
Owner name: INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |